BIOMARKER:

IFNG gene signature overexpression

IFNG gene signature overexpression IFNG gene signature overexpression	Lymphoma Lymphoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Head and Neck Cancer Head and Neck Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Cervical Cancer Cervical Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Urothelial Cancer Urothelial Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Melanoma Melanoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Pancreatic Cancer Pancreatic Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Renal Cell Carcinoma RCC	nivolumab + BMS-986205 Sensitive: C3 – Early Trials

Associations